Chengdu Shuode

Sodit Pharmaceutical is a clinical-stage biotechnology company headquartered in Chengdu, China, focused on developing innovative small molecule drugs for metabolic diseases and oncology. The company's primary focus is on the next generation of oral incretin mimetics, aiming to replace injectable peptide treatments with more convenient oral small molecules. Its lead candidate, SD-101, is a potent and selective small molecule GLP-1 receptor agonist currently undergoing Phase 1 clinical trials for type 2 diabetes and obesity. Sodit's pipeline also includes a dual GLP-1/GIP receptor agonist and several early-stage programs in the oncology space. By leveraging structure-based drug design, the company aims to address significant unmet needs in the global metabolic market.